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a b s t r a c t
The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to
biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets.
In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl2(OH)2(NH3)2],
3, and a carboxylate-modiﬁed analog, c,t,c-[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2], 4, by ascorbic acid (AsA)
or glutathione (GSH). Since carbonate plays a signiﬁcant role in the speciation of platinum complexes in
solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer
195
in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (conﬁrmed using Pt NMR), which
binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2
195
intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, Pt NMR shows
that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular
DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiolog13
ical carbonate is present in the reduction medium, C NMR shows that Pt(II) carbonato complexes form
which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV)
complexes to act as prodrugs for cisplatin are discussed.
© 2011 Elsevier Inc. All rights reserved.

1. Introduction
In the earliest reports of the anticancer effects of cisplatin, cis[PtCl2(NH3)2], 1, Fig. 1, Rosenberg and coworkers noted that certain
complexes containing Pt(IV) exhibit potent antitumor activity [1–5].
Since complexes of Pt(IV) are slow to exchange their bound ligands,
a central question concerning the mechanism of action of these
compounds is how they may be activated in vivo to produce their
antitumor effects. Tobe and Khokhar [6], and later Cleare et al. [7],
suggested that Pt(IV) complexes may be reduced to Pt(II) complexes
in vivo and the latter exert their cytotoxic effects in a manner analogous to cisplatin and its analogs. The reduction hypothesis was reinforced when it was observed that patients receiving the Pt(IV)
complex, iproplatin, cis, trans, cis-[PtCl2(OH)2((CH3)2CHNH2)2], 2,
Fig. 1, in clinical trials had, cis-[PtCl2((CH3)2CHNH2)2], in their plasma
and urine indicating that 2 was reduced in the body to a Pt(II) complex [8,9].
Ascorbic acid, which is present in blood plasma (50–150 μM) and
the cytosol (~1 mM) [10,11], is a two-electron reducing agent capable
of reducing Pt(IV) to Pt(II). In the case of iproplatin and the related
complex oxoplatin, cis, trans, cis-[PtCl2(OH)2(NH3)2], 3, Blatter et al.
195
[12] used Pt NMR and other techniques to show that ascorbate
reduces these Pt(IV) complexes to cis-[PtCl2((CH3)2CHNH2)2], and
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cisplatin, respectively, and that the reduction products can bind
to and unwind closed circular PM2 DNA. Green and Evans [13]
and Choi et al. [14] measured the second order rate constant for the
ascorbate reduction of iproplatin at 40 °C obtaining k = 0.33 and
0.103 M − 1 s − 1, respectively, while Weaver and Bose [15] investigated the mechanism of reduction of both 2 and 3 by ascorbate. The later
study concluded that reduction of the Pt(IV) compounds by ascorbate
proceeds by an outer sphere mechanism with a rate constant similar
to those earlier reported but [13,14], after some Pt(II) is produced
in the reaction mixture, the reduction is greatly accelerated by the
ability of Pt(II) species to serve as catalysts for the further rapid
reduction of Pt(IV) to Pt(II).
The typical concentration of the tripeptide, glutathione (GSH),
γ-glutamylcysteinylglycine, which contains a cysteine thiol residue,
is ~2 mM in the cytosol and ~ 850 μM in blood [2,16]. Reduced GSH
is a potent one-electron reducing agent and, while it is capable of
reducing Pt(IV) to Pt(II), the nature of the GSH-produced reduction
products has been the subject of inquiry [3]. Recently, Volckova,
et al. [17] used a variety of physical techniques to show that GSH
rapidly reduces iproplatin, 2, to produce cis-di(isopropylamine)
chloro-glutathionatoplatinum(II) which has the thiolate of a GSH
molecule bound to Pt(II). Since this type of complex could not form
a 1, 2 intrastrand crosslink with DNA [18], it was suggested that
GSH-reduced iproplatin may exhibit its cytotoxic effects by modifying
biological targets other than DNA in the cell. As the work described in
this manuscript was being ﬁnalized, Nakai, et al. [19], reported that
the reduction by GSH of the Pt(IV) complex cis-[PtCl4(NH3)2], which
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In this report we examine the ability of oxoplatin, 3, and one of its
carboxylate modiﬁed analogs, 4, Fig. 1, to produce cisplatin in the
presence of the biologically common reducing agents, ascorbic acid,
AsA, and glutathione, GSH. Oxoplatin exhibits potent oral anticancer
activity [29,30] and 4 and its analogs have been used in a host of
drug delivery applications involving nanotechnology [24–28]. Since
Pt(II) complexes bind to DNA, we use pBR322 DNA as a capture
agent for the reduction products of 3 and 4 and measure the mobility
of the platinated DNA forms in an agarose gel. Since it is known that
physiological carbonate plays a signiﬁcant role in the speciation of
cisplatin in solution which affects the kinetics of the platinum–DNA
interaction and possibly the nature of the DNA adduct formed
[31–36], we also investigated platinum binding to pBR322 DNA in
the presence and absence of carbonate buffer. In addition to using a
closed circular DNA and gel electrophoresis to detect the effects of
195
the reduction products on DNA mobility, we also used Pt NMR to
identify the nature of the platinum species formed in the reduction
13
and C NMR to detect Pt(II) carbonato complexes when the reduction
is carried out in carbonate media.
2. Materials and methods

Fig. 1. Structures of the platinum compounds in the study.

2.1. Synthesis of oxoplatin (3)
is considered a prodrug of cisplatin, actually does not produce cisplatin. The study also showed that if calf thymus DNA is present in the
reduction medium, the Pt(II) product produced in the reaction
which is captured by DNA does not form the 1, 2 intrastrand DNA
crosslink.
While both ascorbic acid and GSH are small molecule reducing
agents often cited in connection with the reductive activation of
Pt(IV) complexes, Gibson and coworkers [20,21] monitored the rate
of reduction of Pt(IV) complexes in extracts obtained from whole
cells. These investigators found that reductive elimination of cis-diam
(m)inedichloridoplatinum(IV) complexes with axial acetato ligands
by whole cell extracts does exclusively produce a Pt(II) product with
the expected, cis-PtCl2N2 geometry.
In considering the activation of Pt(IV) complexes, Platts et al. [22],
correlated the electrochemical peak potentials and octanol-water
partition coefﬁcients of 31 Pt(IV) complexes having the potential to
produce cisplatin or cisplatin-type complexes through reductive
elimination to Pt(II) compounds. These investigators found a good
correlation between the aforementioned properties and the calculated surface area, orbital energies, dipole moments and atomic partial
charges of the compounds and suggested that the models developed
in the study have the potential to predict the antiproliferative properties of the compounds from calculated data.
When compared to Pt(II) compounds, complexes containing
Pt(IV) have relatively slow ligand exchange rates, a feature that
allows chemical modiﬁcation of the bound ligand without breaking
the metal-ligand bond. For example, in the synthesis of the drug candidate, satraplatin, hydroxide ion bound to Pt(IV) serves as a nucleophile for reaction with acetic anhydride, in the process converting the
hydroxo ligand to an acetato ligand [2,23]. The exchange inertness of
ligands bound to Pt(IV) is also playing an increasingly important role
in new strategies for delivering platinum drugs to cancer cells involving nanotechnology [24–28]. An approach often employed is to chemically modify one of the ligands attached to a Pt(IV) complex and to
tether many copies of the modiﬁed complex to a nanoparticle. Since
a nanoparticle has numerous attachment sites, some of which can
be equipped with a vector capable of targeting a speciﬁc cell type,
the nanoparticle becomes an efﬁcient vehicle for transporting many
copies of a platinum complex inside the cell. If the Pt(IV) compound
attached to the nanoparticle is designed to release cisplatin upon
reduction, the nanoparticle becomes a “super prodrug” for cisplatin
capable of delivering many copies of the potent anticancer drug to
the interior of the cell.

This compound was synthesized in a manner analogous to that
earlier reported by Brandon and Dabrowiak [37]. Hydrogen peroxide
(30 wt.%, 20 mL) was added dropwise to a suspension of cisplatin,
1, (0.4 g, 1.33 mmol) in H2O (12 mL) at 60 °C. After 4 h, the bright
yellow solution was cooled at room temperature overnight to afford
yellow crystals. The crystals were recovered by ﬁltration and washed
with ice cold water. Yield: 65.6% (0.291 g, 0.872 mmol). IR 3458
(s, OH stretch), 1072 (m, Pt-OH bend), 536 (m, Pt-N(O) stretch).
195
Pt NMR (500 MHz, D2O), δ (ppm) = 853.
2.2. Synthesis of c,t,c-[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2], (4)
This compound was synthesized in a manner analogous to that
described by Dhar et al. [25]. To a suspension of compound 3 (0.2 g,
0.6 mmol) in DMSO (16 mL) was added succinic anhydride (0.06 g,
0.6 mmol) and the mixture was stirred overnight at RT to afford a
bright yellow solution. After reducing the volume of the solution in
vacuo to ~0.5 mL, addition of ~ 10 mL of ice cold acetone caused precipitation of a pale yellow solid, which was collected via ﬁltration,
washed with acetone and dried in vacuo. Yield: 97.2% (0.253 g,
1
0.583 mmol). H NMR (300 MHz, DMSO-d6), δ (ppm) = 5.92 m, 6H
1
195
1
14
(NH3); 2.39 m, 4H (CH2). J( H- Pt) = 103.2 Hz, J( H- N) = 25.5 Hz.
13
C NMR (75 MHz, DMSO-d6): δ = 179.73 (C=O), 174.19 (C=O),
30.21 (CH2), 31.24(CH2) ppm. MS (1:1 THF:MeOH with NaCl) calculated m/e of (C4H12N2O5Cl2Pt)Na + = 456.0, observed m/e = 456.0.
195
Pt NMR, δ (ppm) = 943.
2.3. DNA binding studies
The DNA binding/capture studies were done in a total volume
of 20 μL containing 38.5 μM (bp) pBR322 DNA (New England
BioLabs Inc.), in 12 mM HEPES, N-(2-hydroxyethyl)-piperazine-N'-2ethanesulfonicacid (pH 7.4) buffer or, when sodium bicarbonate
was present, in 12 mM HEPES buffer plus 12 mM sodium bicarbonate
(pH 7.4). The two reducing agents used were glutathione (GSH,
2 mM) and ascorbic acid (AsA, 50 μM). Cisplatin, 1, was used as purchased (Sigma-Aldrich, St. Louis, MO). Stock solutions of the platinum
compounds in distilled water, 1 and 3, or DPBS (Dulbecco's phosphate
buffered saline) buffer, 4, were in the range of 40–650 μM. Appropriate volumes of the stock solutions were added to solutions containing
the buffer and DNA to give the ﬁnal concentrations given earlier and
values of r, where r = [platinum compound]/[DNA-bp], given in the
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captions to ﬁgures. The samples were incubated at 37 °C for 24 h in
sealed Eppendorf tubes after which time 2.5 μL of a loading dye
containing 50% glycerol, 0.25% bromophenol blue and 0.25% xylene
cyanol was added. An 8 μL volume of each sample containing the
loading dye was loaded in the wells of a 1% agarose gel. Electrophoresis was carried out for a period of ~ 4 h, at 100 V. After electrophoresis,
the gel was immersed in 300 mL of deionized water containing 300 μL
of a 0.5 mg/mL solution of ethidium bromide for 30 min to stain the
DNA, and then soaked in water alone for 15 min to de-stain the background of the gel. A digital image of the stained gel was captured
using a Kodak Gel Logic 100 imaging system equipped with Fisher
Biotech IT-88A transilluminator.
2.4. Instrumentation
1

One dimensional H NMR was obtained using a Bruker Avance
300 MHz spectrometer with chemical shifts determined by setting
the hydrogen impurity in DMSO-D6 to 2.50 ppm. One dimensional
195
Pt NMR spectra were recorded on a Bruker Avance 500 MHz NMR
instrument utilizing either a Nalorac 5 mm indirect detection gradient probe or a Nalorac 10 mm broadband observe probe. A solution
of 10 mM potassium hexachloroplatinate in 95% H2O/5% D2O was
used as an external standard (0 ppm). All experiments were done
at 25 °C using a 2 s relaxation delay time and a spectral width of
600 ppm with 32 K points. One dimensional carbon-13 NMR spectra
were recorded at 25 °C on a Bruker Avance 500 MHz NMR instrument
13
equipped with a 5 mm Bruker QXI gradient probe. The standard C
pulse sequence was used with proton broad-band decoupling and a
spectral window of 250 ppm. The relaxation delay was set to 2 s,
the total number of points to 16 K, and the total number of scans
set to 6000. The internal chemical shift standard, set at 126.1 ppm,
13
was CO2(aq). Infrared spectra were obtained on nujol mulls using a
Nicolet 200 FT-IR spectrometer and the mass spectral data were
obtained using positive electrospray ionization with a Bruker 12
Tesla APEX-Qe FTICR-MS with an Apollo II ion source (COSMIC Lab,
Norfolk, VA).
2.5.

195

Pt NMR

Compound 3 (10 mM) was incubated at 37 °C for 24 h in the presence of 10 mM ascorbic acid or 20 mM GSH in 12 mM HEPES buffer
with or without 12 mM NaHCO3, pH 7.4. Compound 4 (10 mM) was
incubated at 37 °C for 24 h in the presence of 10 mM ascorbic acid
or 20 mM GSH in DPBS buffer with or without 12 mM NaHCO3, pH
7.4. The solvent of the aforementioned samples was H2O/D2O (95/5)
and the concentrations given are the ﬁnal concentrations.
13

2.6. C NMR
Compound 3 (10 mM) was incubated at 37 °C for 24 h in the presence of 10 mM ascorbic acid in 12 mM HEPES buffer with 0.5 M
NaH 13CO3, pH 7.4. Compound 4 (10 mM) was incubated at 37 °C for
24 h in the presence of 10 mM ascorbic acid in DPBS buffer with
0.5 mM NaH 13CO3, pH 7.4. The solvent of the aforementioned samples was H2O/D2O (90/10); the ﬁnal concentrations in the reaction
mixture are given.
3. Results
3.1. DNA capture–gel electrophoresis experiments
Fig. 2(a)–(e)shows images of agarose gels of pBR322 DNA in the
presence of reducing agents and either 3 or 4 in the presence and
absence of carbonate while Fig. 2(f) shows the binding of cisplatin,
1, to pBR322 DNA in the presence and absence of GSH. Fig. 3(a)–(f)
shows mobility plots, in which the distance of migration of the DNA

form from the loading well in arbitrary units is plotted versus r,
where r = [Pt]/[DNA-bp], with linear ﬁts to the data. Since the concentrations of DNA, the reducing agent, carbonate (when present)
and time are constant in the experiments, the plots show changes
in DNA mobility as a function of the total concentration of Pt(IV) complex initially present in the reaction medium. In these experiments
the closed and nicked circular forms of pBR322 DNA were simply
used as capture agents for the reduction products, in this case Pt(II)
compounds, which bind to the DNA forms and affect their mobilities
in the gel. Since electrophoresis conditions varied slightly from experiment to experiment which changed the distance of migration in the
gel, the linear ﬁts to the data in Fig. 3 were divided by the y-intercept
to give relative slopes. The relative slopes, with statistical errors, are
given in Table 1.
The agarose gel of pBR322 DNA with oxoplatin, 3, reduced by
ascorbic acid (AsA) is shown in Figs. 2(a) and 3(a) and Table 1 give
the mobility plots and their relative slopes. When carbonate is
present, the relative slopes of Form I and II are zero indicating that
mobility is independent on r suggesting that the Pt(II) species produced in the reduction are not binding to DNA.
When carbonate is absent from the medium Form I is difﬁcult
to observe, Form II runs slightly faster than its counterpart without
carbonate and its relative slope is positive (the mobility of DNA
increases with r), Table 1. While the increase in mobility and positive
slope of Form II is consistent with the formation of the well-known
cisplatin 1, 2 intrastrand crosslink, the difﬁculty in detecting Form I
(a weak band for this form is observed in lane 12) suggests that
Form I is co-migrating with Form II at some values of r and/or the
crosslink blocks ethidium bromide binding to DNA leading to reduced
195
staining [34]. Pt NMR shows that the reduction of 3 with AsA
13
produces cisplatin and its aquated/substituted products and C
NMR indicates that in carbonate media Pt(II) carbonato complexes
are present (vide infra).
Figs. 2(b) and 3(b) and Table 1 give the results of the DNA capture
experiment when the oxoplatin analog, 4, is reduced by AsA in the
presence and absence of carbonate. In the absence of carbonate,
Figs. 2(b) and 3(b) show that the mobilities of both DNA forms are
much different than the controls indicating that binding of Pt(II) to
DNA is taking place. However, as is evident in Table 1, the slope for
Form II is zero while the slope for Form I is likely positive. In this
DNA capture experiment, the stock solution of 4 was in DPBS, which
contains chloride ion. Since the chloride ion suppressed the aquation
of cisplatin and [Cl −] is proportional to r in the reaction medium, the
crosslink appears to be formed but there is not much change in the
mobility of Form I with r. When carbonate is present in the reduction
reaction, mobilities are like those of the controls with the slope of
Form I zero and the slope of Form II small and positive with a substan195
tial uncertainty. Pt NMR shows that the reduction of 4 with AsA
13
produces cisplatin (not its aquated/substituted products) and C
NMR indicates that in carbonate media Pt(II) carbonato complexes
are present (vide infra).
Figs. 2(c) and 3(c) and Table 1 show the effects on pBR322 DNA
mobility when 3 is reduced with GSH. In the presence of carbonate,
the mobilities of both forms are like controls with the relative slope
of Form I zero and the slope of Form II weakly positive (with a significant error) showing that 12 mM carbonate blocks or impedes the
interaction of Pt(II) products with DNA. However, when carbonate
is absent from the reaction mixture, the mobility of Form I is slower
than the control and its relative slope is negative (mobility decreases
with r) while the slope of Form II is positive (mobility increases with r).
195
Pt NMR analysis shows that reduction of 3 with GSH does not produce
cisplatin (vide infra).
Figs. 2(d) and 3(d) show the gel and mobility plots when oxoplatin analog, 4, is reduced by GSH. When carbonate is present, the
mobilities of both forms are similar to those of the controls but the
slopes of both forms are only weakly positive consistent with little
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platinum binding to DNA, Table 1. When carbonate is absent, the
mobilities of both forms appear shifted from controls and the relative
slopes of both forms are signiﬁcant with Form I having a positive
slope (mobility increases with r) and Form II a negative slope, opposite to what is observed for 3 being reduced by GSH Figs. 2(c) and
3(c), Table 1.
In an effort to better understand the DNA capture experiment
involving the reduction of 4 by GSH in the absence of carbonate, a
larger number of values of r were investigated, (see Figs. 2(e) and
3(e) and Table 1). It is evident that both forms are shifted from
the controls and their mobilities change systematically with r. From
linear ﬁts of the mobilities to r, Form I has a positive slope while

9

Form II has a negative slope with signs and magnitudes comparable
to those observed in Figs. 2(d) and 3(d) and Table 1. However closer
inspection reveals that the mobility is weakly bimodal in nature with
much better ﬁts to the data being obtained by two lines, one for r b 3.3
and a second for r > 3.3 (see Table 1). While the mobility of Form I
moves closer to that of Form II for higher r, the two forms never
195
co-migrate. Pt NMR analysis shows that reduction of 4 with GSH
does not produce cisplatin (vide infra).
Figs. 2(f) and 3(f) show cisplatin binding to pBR322 DNA in the
presence and absence of GSH; the relative slopes of the mobility
plots are given in Table 1. In the absence of GSH, the mobility of
Form I is much lower than the control and Forms I and II nearly comigrate at r = 0.9. Table 1 also shows that the sizes of the relative
slopes of both forms are much larger than any other relative slope
showing that the effect of the drug on the mobility of the form is
very large. This is due to the formation of the 1, 2 intrastrand crosslink. Since the slope of Form I is positive, the writhe is positive
which indicates that there is a high loading of platinum on DNA
[38,39]. The negative slope for Form II is also consistent with a high
loading of platinum on DNA.
Figs. 2(f) and 3(f), show the effects of cisplatin, 1, in the presence
of GSH on Forms I and II and Table 1 gives the slopes of the mobilities.
Both Forms I and II have large negative and positive slopes, respectively, which is the same slope pattern observed for the reduction of
3 with GSH in the absence of carbonate. This suggest that some
cisplatin may also be produced in the reduction of 3 with GSH and
that possibly a cisplatin-GSH complex is interacting with DNA.
3.2.

195

Pt NMR

195

Pt NMR was used to identify the nature of the platinum species
in solution when 3 and 4 are reduced by either AsA or GSH. The incubation time of the reduction solution was 24 h, following which time
NMR spectra were obtained; the solutions contained no DNA. Also,
the ratio of reducing agent to platinum complex was 1:1 for AsA
reducing 3 and 4 and 2:1 for GSH reducing 3 and 4, much different
than the ratios employed in the DNA capture-gel studies. The choice
of ratios of reducing agent to platinum was largely inﬂuenced by
195
the relatively low sensitivity of Pt NMR which required millimolar
concentrations of the platinum complex in the NMR tube. The concentration of the reducing agent, if the ratios used in the gel studies
were to be maintained, would be unrealistically large. In these

Fig. 2. (a)–(f) Ethidium bromide stained agarose gels of pBR322 DNA (38.5 μM). (a)–(e),
pBR322 DNA in the presence of either 3, or 4, in the absence or presence of 12 mM sodium
bicarbonate with either ascorbic acid, AsA (50 μM) or glutathione, GSH (2 mM) as the
reducing agent. The fastest migrating band (bottom band) is covalently closed circular
form I DNA while the slowest migrating band (top band) is nicked circular form II DNA.
(a) Compound 3, AsA, sodium bicarbonate, lanes 5–11; no bicarbonate, lanes 12–18.
For this and the subsequent gels, lane, r, i.e., the lane number followed by r where, r =
[compound]/[DNA-bp], are given. Lane, r: 5, 0.26; 6, 0.52; 7, 1.04; 8, 1.17; 9, 1.30;
10, 1.43; 11, 1.56; 1, 0 (DNA); 2, 0 (DNA + AsA); 3, 0 (DNA+ bicarbonate); 4, 0 (DNA +
AsA + bicarbonate). The values of r for lanes 12–18 are the same as for lanes 5–11.
(b) Compound 4, AsA, sodium bicarbonate, lanes 5–11; no bicarbonate, lanes 12–18. Lane,
r: 5, 0.26; 6, 0.52; 7, 1.04; 8, 1.17; 9, 1.30; 10, 1.43; 11, 1.56; 1, 0 (DNA); 2, 0 (DNA+ascorbic
acid); 3, 0 (DNA+ bicarbonate); 4, 0 (DNA+ ascorbic acid +bicarbonate). The values of r
for lanes 12–18 are the same as for lanes 5–11. (c) Compound 3, GSH, sodium bicarbonate,
lanes 5–11; no bicarbonate, lanes 12–18. Lane, r: 5, 1.69; 6, 3.38; 7, 5.06; 8, 6.75; 9,
7.60; 10, 8.44; 11, 10.13; 1, 0 (DNA); 2, 0 (DNA+GSH); 3, 0 (DNA+bicarbonate); 4,
0 (DNA+GSH+bicarbonate). The values of r for lanes 12–18 are the same as for lanes
5–11. (d). Compound 4, GSH, sodium bicarbonate, lanes 5–9; no bicarbonate, lanes
12–18. Lane, r: 5, 1.30; 6, 2.60; 7, 3.90; 8, 5.19; 9, 5.84; 10, 6.49; 11, 7.79; 1, 0 (DNA); 2,
0 (DNA+GSH); 3, 0 (DNA+bicarbonate); 4, 0 (DNA+ GSH+bicarbonate). The values of
r for lanes 12–18 are the same as for lanes 5–11. (e). Compound 4, GSH. Lane, r: 3, 1.30; 4,
1.49; 5, 1.69; 6, 1.88; 7, 2.08; 8, 2.27; 9, 2.60; 10, 2.92; 11, 3.25; 12, 3.57; 13, 3.90; 14, 4.22;
15, 4.55; 16, 4.87; 17, 5.19; 18, 5.52; 1, 0 (DNA); 2, 0 (DNA+GSH). (f) Compound 1, cisplatin,
2 mM GSH in 12 mM HEPES buffer, pH 7.4, lanes 3–9; no GSH, lanes 11–17, the values of
r for lanes 3–9 and 11–17 are the same (condition error, lane 13). Lane, r: 3 (11), 0.08;
4 (12), 0.09; 5 (13), 0.10; 6 (14), 0.11; 7 (15), 0.12; 8 (16), 0.13; 9 (17), 0.14; 1 (10),
0 (DNA), 2, 0 (DNA+GSH).
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Fig. 3. Distance of migration of the band from the loading well in the gel in arbitray units as a function of r, where r = [Pt]/[DNA-bp], referred to as mobility plots, for the agarose gels
shown in Fig. 2. The lines shown are linear ﬁts to the data. Square is closed circular Form I pBR322 DNA in the presence of carbonate; triangle is Form I DNA without carbonate; circle
is nicked circular Form II DNA in the presence of carbonate; diamond is Form II DNA in the absence of carbonate.

Table 1
Relative slopes (slope divided by the y-intercept) from the mobility plots shown in
Fig. 3, with statistical errors.
Systema

Form Ib

Form II

Form I + HCO3−

Form II + HCO3−

AsA and
3 (a)
AsA and
4 (b)
GSH and
3 (c)
GSH and
4 (d)
GSH and
4 (e)

No data

45 ± 15 (+)

7.8 ± 5.2 (0)

3.6 ± 4.4 (0)

13.2 ± 7.5 (+)

6.1 ± 12.4 (0)

− 9.4 ± 10.4 (0)

11.4 ± 7.3 (+)

0.9 ± 1.2 (0)

3.0 ± 1.5 (+)

− 3.3 ± 1.2 (−) 6.2 ± 0.6 (+)
18.0 ± 3.5 (+)

− 11.1 ± 4.0 (−)

1.6 ± 0.7 (+)

1.9 ± 0.5 (+)

15.5 ± 2.4c(+)

− 9.2 ± 3.4c(−)

no data

no data

Form I + GSH
Cisplatin (1.92 ± 0.96) ×
(f)
103(+)

Form II + GSH
− 260 ± 110 (−) − 960 ± 340 (−) 630 ± 100 (+)

a
Refers to the reducing agent and the Pt(IV) compound involved in the reduction
reaction; the letter in parenthesis refers to the gel image in Fig. 2 and the mobility
plot in Fig. 3. The values given in the table are relative slopes of the linear ﬁts to the
mobility plots shown in Fig. 3 in units of r− 1 multiplied by 103, followed by the sign
of the slope in parentheses, r = [Pt]/[DNA-bp]. Positive and negative slopes indicate
that the DNA form migrates faster and slower, respectively, with increasing r, than
the same form in the absence of added platinum compound. bForm I and Form II are
closed and nicked circular pBR322 DNA, respectively. cFor (e), a much better ﬁt (sum
of square deviations = 60 instead of 377) is obtained by using one line for r b 3.3 and
a second for r > 3.3).

reactions, ascorbic acid acts as a two electron reducing agent to
convert one molecule of a Pt(IV) complex to a Pt(II) product and
the AsA is oxidized to dehydroascorbic acid [15]. In the case of the
reduction of the Pt(IV) complex with iproplatin, 2, three molecules
of GSH are required to completely reduce one molecule of 2. Two
GSH molecules supply the two electrons necessary to convert Pt(IV)
to Pt(II) (producing the disulﬁde, GSSG), and one molecule of
GSH, in its deprotonated form, becomes bound to Pt(II) to give as
the ﬁnal product, cis-di(isopropylamine)chloro-glutathionatoplatinum(II), cis-[PtCl(GS)(NH2CH(CH3)2)2], [17].
195
The Pt NMR spectra of the platinum species observed in the
reduction reactions are shown in Fig. 4. Fig. 4(a) shows that the reaction of 3 with AsA in 12 mM HEPES buffer produces a strong signal
for cisplatin at −2140 ppm, a number of weak signals for Pt(II) species in the region −1670 to −1830 ppm having a PtN2O2 coordination environment [40], and a weak signal for unreacted 3, at 853 ppm.
Interestingly, when two equivalents of GSH are used as the reducing agent for oxoplatin, only a signal of reduced intensity for 3 is
195
observed in the Pt NMR spectrum at 853 ppm, i.e., no Pt(II) products are observed, Fig. 4(d). Although an exhaustive search in the
chemical shift range −4000 to 1500 ppm failed to ﬁnd additional
195
Pt NMR resonances, the electrophoresis results clearly show that
some Pt(II) complexes are produced in the reduction and that they
bind to DNA, Figs. 2(c) and 3(c) and Table 1.
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195

Fig. 4. Pt NMR spectra. (a) Reduction of oxoplatin, 3, with AsA. (b) Reduction of oxoplatin, 3, with GSH. (c) Reduction of the oxoplatin analog, 4, with AsA. (d) Reduction of the
oxoplatin analog, 4, with GSH.
195

Fig. 4(c) shows the Pt spectrum of the oxoplatin analog, 4, 24 h
after exposure to one equivalent of AsA in DPBS buffer. As is evident
195
from the ﬁgure, the only detectable Pt NMR signal is the strong
peak at −2140 ppm which due to cisplatin. The absence of the
Pt(IV) starting material at 943 ppm shows that the reaction of 4 with
AsA went to completion. In addition, the lack of Pt(II) aqua species
and/or cisplatin reaction products with ascorbate or dehydroascorbic
acid, as in Fig. 4(a), shows that the presence of a high concentration
of chloride ion, ~140 mM, in DPBS, suppresses the reaction of cisplatin
with components in solution, keeping the drug in its dichloro form.
195
The Pt NMR spectrum of the reaction of 4 with two equivalents
of GSH for 24 h in DPBS buffer only exhibits a resonance (of reduced
intensity) for the unreacted complex, 4, at 943 ppm, i.e. no resonances for cisplatin/other Pt(II) complexes are observed, Fig. 4(d).
13

3.2. C NMR
195

In addition to Pt NMR, the reduction of 3 and 4 with AsA, which
13
produces cisplatin, was monitored with C NMR in the presence of
13
−
H CO3 . Fig. 5 shows that the reduction of either compound with
AsA produces a number of Pt(II) carbonato complexes which have resonances on the low ﬁeld side of free bicarbonate ion at 162.0 ppm
[31,33]. Reduction of 3 in carbonate produces carbonato resonances
at, 168.1–168.7 ppm, while reduction of 4 with AsA gives a group of
carbonato resonances in the region 167.2–169.7 ppm. Since carbonato
13
complexes reduce the binding of cisplatin to DNA [34–36], the C NMR
results explain the observed decrease in binding of Pt(II) compound to
DNA when carbonate is present in the reduction medium, Figs. 2 and 3
and Table 1.

4. Discussion
In this report we show that the biologically common reducing
agent ascorbic acid reduces oxoplatin, 3, and one of its analogs having
an attached carboxylate ligand, 4, to cisplatin but that treatment of
the Pt(IV) compounds with glutathione does not produce cisplatin.
While the Pt(II) product(s) produced by GSH bind to closed circular
pBR322 DNA, the gel analyses show that they do not form the wellknown 1, 2 intrastrand DNA crosslink that is characteristic of cisplatin
binding to DNA. We also show that reduction of 3 and 4 in the presence of physiological carbonate prevents binding of the Pt(II) products to pBR322 DNA. Collectively, these observations limit the
conditions under which oxoplatin and one of its analogs that is useful
in nanotechnology can serve as prodrugs of cisplatin.
Bose and coworkers [15] studied the kinetics and mechanism of
reduction of oxoplatin, 3, with ascorbic acid and iproplatin, 2, with
glutathione. These researchers showed that AsA reduces 3 with a
second order rate constant of ~ 2 M − 1 s − 1 at pH 7.3 at 22 °C and
that cisplatin is produced by the reduction. Fig. 5 shows that cisplatin
195
is indeed produced in the reduction and Pt NMR further indicates
that the drug reacts during the 24 h reaction period to produce Pt
(II)N2O2 type products which appear to be aquated and/or carboxyl
substituted products of the drug, the carboxylate ligand most likely
being supplied by dehydroascorbic acid [40]. Interestingly, not all 3
has been reduced to Pt(II) products as evidenced by the relatively
weak resonance at 853 ppm, Fig. 5, although this reduction reaction
would be expected to have an approximate half-life of ~ 1 min under
195
the conditions of the Pt NMR experiment ([AsA], [3] = 10 mM,
37 °C). It is possible that either the stoichiometry of the reduction is

12
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Fig. 5. C NMR spectra of the products of reduction of 3 (top spectrum) and 4 (bottom spectrum) with ascorbic acid in the presence of NaH13CO3.

not 1:1 or there is a stoichiometric imbalance in the amounts of 3 and
AsA in the reaction mixture. Since aquated and/or carboxyl substituted products of cisplatin should react with DNA to form the 1, 2 intras195
trand crosslink, the Pt NMR results reinforce the interpretation of
the gel DNA mobility studies that suggest that the reduction product
of 3 with AsA produces the crosslink, Figs. 2(a) and 3(a) and Table 1.
Fig. 4(b) shows that when oxoplatin is reduced by GSH using a 1:2
ratio of reactants, only a weakened signal for 3 at 853 ppm is ob195
served in the Pt NMR spectrum. While it is evident that a reaction
195
has occurred, no Pt(II) products were observed in the Pt NMR spectrum. In the case of the related complex, iproplatin, 2, reduction with
GSH occurs with a second order rate constant of 0.49 M − 1 s − 1
at 22 °C at pH 7.0 with three molecules of GSH being required to reduce one equivalent of 2 to produce, cis-di(isopropylamine)chloroglutathionatoplatinum(II) [17]. Since iproplatin, 2, and oxoplatin, 3,
have similar structures, it is reasonable to assume that 3 would also
react with GSH in a 1:3 stoichiometry which explains the peak at
195
853 ppm as due to unreacted oxoplatin in the Pt NMR experiment.
Furthermore if the rates of reaction for 2 and 3 with GSH are similar,
195
the t1/2 of the reaction of 3 with GSH under the conditions of the Pt
NMR experiment ([GSH], [ 3] =10 mM, 37 °C) is ~3 h, so that the
reaction is complete. Although Volckova et al. [17] show that reduction of 2 with GSH produces cis-di(isopropylamine)chloroglutathionatoplatinum(II), the corresponding Pt(II) complex for
the reduction of 3, cis-diamminechloro-glutathionatoplatinum(II),
cis-[PtCl(GS)(NH3)2], is not observed in Fig. 4(b) (its resonance
would be expected at ~−3000 ppm [40]). Failure to observe the
195
Pt(II) product (s) in the Pt NMR spectrum most likely means
that although the Pt(II)-GSH adduct is formed, due to the polydentate nature of GSH and the long reaction period, 24 h, it converts
to other species that have too low intensity to be detected in the

NMR experiment. The DNA capture experiments clearly show that
a Pt(II) complex is produced in the reaction, and is captured by
DNA, but its effect on the supercoiling of DNA is not like that of cisplatin, i.e., the 1, 2 intrastrand crosslink is not formed, Fig. 2(f),
Table 1[2,34–36]. If the initial reduction product in the reaction is
cis-[PtCl(GS)(NH3)2], it could react with DNA through the loss of
the chloride ligand to produce a monofunctional adduct, which
because of the presence of the thiolate ligand, would be unlikely
to yield an intrastrand crosslink.
The reduction of 4 by AsA mirrors that of oxoplatin except that
195
only cisplatin is observed in the Pt NMR spectrum, Fig. 5(c), showing that the reaction is complete. The absence of hydrolysis products
and/or reaction products of cisplatin is explained by the high chloride
195
concentration in the DPBS buffer (~140 mM) in the Pt NMR sample.
Since the reduction of 4 with AsA in the presence of DNA (no carbonate) was carried out in a HEPES buffer with some DPBS added with 4,
some reactive Pt(II) species should be present which explains
the shift of Form I DNA relative to its control, Figs. 2(b) and 3(b).
However, in this case mobilities are essentially independent of r.
This is because, in the DNA reaction mixture, [Cl −] is proportional
to r, and since chloride suppresses DNA binding, mobilities are not
very sensitive to r, Table 1.
195
The Pt NMR spectrum of the reduction of 4 with GSH is similar to
that of 3 with the tripeptide in that only some of the Pt(IV) complex
remains after 24 h in the NMR solution. While this agrees with the
reaction stoichiometry of 2 with GSH, Volckova et al. [17], i.e., some
Pt(IV) should remain unreacted, Pt(II) products are not observed in
the NMR spectrum. However, when the reduction is carried out in
the presence of DNA without carbonate, DNA captures a Pt(II) complex, but the bound platinum does not affect mobility in the same
way as the intrastrand crosslink, i.e. Forms I and II never co-migrate
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at any value of r, Figs. 2(d,e) and 3(d,e), Table 1. By analogy with
the reaction of 3 with GSH, the Pt(II) product is likely cis-[PtCl(GS)
(NH3)2] which would be expected to bind to DNA in a monofunctional manner (loss of Cl −) and not produce the intrastrand
crosslink.
13
Fig. 5 shows C NMR spectra of reductions of 3 and 4 with AsA in
13
the presence of C-labeled carbonate. As is evident from the spectra,
the reduction results in the formation of Pt(II) carbonato complexes
13
which exhibit characteristic C NMR resonances in the region
167.2–169.7 ppm, on the low ﬁeld side of H 13CO3−[31,32]. It is well
known that carbonato complexes can form by either a conventional
ligand substitution reaction at the metal center, in which carbonate
is exchanged with a ligand bound to the metal ion, or by a unique
and rapid route in which the oxygen atom of a metal-bound hydroxo
ligand attacks the carbon atom of molecular carbon dioxide, to produce a bound carbonate (hydrogencarbonate) ligand, Fig. 6 [41].
Since the latter reaction does not involve a metal–ligand bond breaking step, it generally occurs with much larger rates than conventional
ligand exchange reactions, which, depending on the metal ion, are in
13
the range, 50–600 M − 1 s − 1[41]. The C NMR spectra in Fig. 5 show
that there are a greater number of distinct carbonato species formed
in the reduction of 4 with AsA than in the corresponding reduction
of 3. The additional carbonato species observed for the former could
be due to the liberated dicarboxylate ligand which could act as a
ligand toward Pt(II) thereby increasing the number of carbonato
products observed in the reaction.
In the period following the initial report of the anticancer activity
of cisplatin, Rosenberg proposed that the anticancer properties of
the drug are due to its ability to form an intrastrand crosslink at
two adjacent purine bases of DNA [1]. Subsequent work by many
research groups over the intervening years conﬁrmed the existence
of this type of lesion, ﬁnding that an adduct at the sequence GG is
most common [2]. The mechanism for cisplatin binding to DNA starts
with the mono-aqua complex, cis-[PtCl(H2O)(NH3)2] +, which reacts
with N-7 of guanine through the loss of a the water molecule to
form the monofunctional adduct cis-[PtCl(G)(NH3)2] +[42]. This DNA
adduct then converts to the 1, 2 intrastrand crosslink, cis-[Pt(GG)
(NH3)2] + 2, directly through the loss of the chloride ligand from Pt
(II) or through an intermediate step involving the aqua complex. If
carbonate is present, the bound water molecule of cis-[PtCl(H2O)
(NH3)2] + may be partially or fully converted into a carbonate form,
through the reaction in Fig. 6, and since carbonate/hydrogencarbonate is a poorer leaving ligand than water [43], binding of the complex to DNA would be reduced. This explains the gel studies that
show that binding is slight when carbonate is present [34–36].
Todd et al. [36] argued that carbonate in the medium does not
change the type of adduct formed on DNA, i.e. the 1, 2 intrastrand
crosslink is formed, but that carbonate only reduces the amount of
the crosslink that forms. However, characterization of the DNA adduct in these studies required techniques (HPLC, mass spectrometry,
etc.) that would allow CO2 gas to escape from the system. This could
shift the equilibria given in Fig. 6 to the left and, the cisplatin-DNA adduct that initially forms in carbonate could have been inadvertently
destroyed in the workup thus producing the 1, 2 intrastrand crosslink. Binter et al. [34], on the other hand, measured mobilities and
band intensities of platinated DNA in gel electrophoresis experiments, concluding that the presence of carbonate causes cisplatin to
form a monofunctional adduct on DNA. While these studies had

-H+
Pt(II) OH2

aqua

H+

13

none of the structural characterization rigor of the study by Todd et
al. [36] they were much less prone to shifts in the chemical equilibrium in Fig. 6. In a following study, Sorokanich et al. [35] were unable to
reproduce the band intensity changes observed by Binter et al. [34]
but the investigators found that at large values of r, Forms I and II
never co-migrate in the gel, again suggesting that the adduct in carbonate is not the same as the 1, 2 intrastrand crosslink. The living
cell maintains a cytosolic concentration of ~12 mM carbonate, of
which dissolved CO2 is an important component, so cisplatin adducts
that form on genomic DNA are exposed to a “carbonate pressure” that
may be difﬁcult to maintain in laboratory experiments. Since carbonate can change the speciation of cisplatin and carboplatin, additional
study on how carbonate inﬂuences the rate and mechanism of the
formation of the DNA adduct and its structure is warranted.
Presently, science is racing to discover new ways of delivering
proven anticancer drugs to tumor sites using nanotechnology
[2,24–28,44]. A reoccurring theme in the case of the platinum drugs
is tethering a Pt(IV) complex of the type exempliﬁed by 4 to a
nano-sized delivery vehicle capable of targeting a cancer cell. While
this strategy promises to uncover exciting new ways for treating cancer, these sophisticated delivery vehicles may not survive passage
through the blood to the tumor site. To date, most studies have
been done using cells growing in culture and since culture medium
contains only a small amount of GSH (~ 3 μM) and no ascorbic acid,
the reducing environment in a cell culture study is very different
than that encountered in chemotherapy.
Using the published rate constants for the reduction of 3 with
ascorbic acid and reduction of iproplatin, 2, with GSH [15,17], it is interesting to speculate on the nature of the Pt(II) products formed if 3
and 4 are present in blood. Although kAsA/kGSH ~ 4, the ratio [AsA]/
[GSH] in blood (plasma) is 100 mM/850 mM = ~ 0.12 [2,10,11,16]
which suggests that only half (4 × 0.12) of the reduction product
would be cisplatin, i.e., reduction by AsA, with the remaining half
being a non-cisplatin complex, formed by GSH reduction. An additional aspect is that the reduction potentials of 3 and 4 are − 0.82
and −0.46 V (NHE) [45,25] respectively, which shows that 4 is
more easily reduced than 3. The reduction potentials for AsA and
GSH are −0.065 V and −0.16 V respectively, so that GSH is a slightly
better reducing agent than AsA [46,47]. Since the circulation time of a
particle in the blood is 1–10 h, there would be ample opportunity for
a compound such as 4 to be reduced on the way to the tumor site
[15,17–19] with much of the reduction product being a thiol adduct
of cisplatin. The platinum “cargo” released from the carrier before
the vehicle reaches its intended target could also reach and kill
tumor cells, which could impart characteristics to the delivery system
that are a combination of both the nano-carrier and the free drug.
In the environment in the cytosol, where [AsA]/[GSH] ~ 1 mM/
2 mM ~ 0.5, the situation found in blood is that the formation of
cisplatin through reduction by AsA is favored by 2 to 1 over the formation of non-cisplatin product through reduction by GSH. If the
nano-carrier with its attached load of Pt(IV) enters the cell intact
and is reduced by intracellular GSH, the commonly cited mechanism,
the expected product would be a cisplatin-GSH adduct and not, as
is often suggested, cisplatin. The likelihood of an intracellular Pt(II)glutathione adduct being formed under these conditions is supported
by the work of Raynaud et al. [48] who showed that the Pt(IV) complex, satraplatin, is reduced inside the cell and that the amount of
intracellular Pt(II)-adduct formed is dependent on the amount of
O
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Fig. 6. Scheme showing the reaction of a Pt(II) aqua species with molecular carbon dioxide and associated equilibria.
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GSH in the cell. While the reaction of GSH with cisplatin is widely
cited as an inactivation mechanism for the drug, implying that the
GSH adduct is not toxic to the cell, such an adduct has one remaining
coordination site (loss of the chloride ligand) for interaction with biological targets in the cell. Given the uncertainty of just how cisplatin
kills cells, formation of a cisplatin-GSH adduct inside the cell could be
sufﬁcient to modify proteins and DNA, impairing their function, thus
causing the cell to enter into apoptosis and die. Professor Dan Gibson
appropriately summed up the progress in the area in a recent paper
titled, “The mechanism of action of the platinum anticancer agents—
What do we really know about it?” [21]. Despite more than 40 years
of research on the mechanism of action of cisplatin and its analogs
we really do need to learn a lot more about how these important
drugs work. This is almost certain to challenge long standing paradigms and, most importantly, open new avenues for ﬁnding more
effective platinum drugs for treating cancer.
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